Gephyrin
From Proteopedia
(Difference between revisions)
Line 23: | Line 23: | ||
[[2fu3]], [[5erq]], [[4pd0]] - rGeph E domain 318-736 - rat<br /> | [[2fu3]], [[5erq]], [[4pd0]] - rGeph E domain 318-736 - rat<br /> | ||
[[2fts]], [[4pd1]], [[1t3e]], [[4u91]] - rGeph E domain + glycine receptor peptide<br /> | [[2fts]], [[4pd1]], [[1t3e]], [[4u91]] - rGeph E domain + glycine receptor peptide<br /> | ||
+ | [[6hso]] - rGeph E domain + glycine receptor peptide + ADP<br / | ||
[[4tk1]], [[4tk2]], [[4tk3]], [[4tk4]], [[4u90]] - rGeph E domain + GABA receptor peptide<br /> | [[4tk1]], [[4tk2]], [[4tk3]], [[4tk4]], [[4u90]] - rGeph E domain + GABA receptor peptide<br /> | ||
+ | [[6hsn]] - rGeph E domain + GABA receptor peptide + ADP<br /> | ||
[[5ers]] - rGeph E domain + AMP<br /> | [[5ers]] - rGeph E domain + AMP<br /> | ||
[[5ert]], [[5err]] - rGeph E domain + ADP<br /> | [[5ert]], [[5err]] - rGeph E domain + ADP<br /> | ||
[[5eru]] - rGeph E domain + ADP + Mo + MoO4<br /> | [[5eru]] - rGeph E domain + ADP + Mo + MoO4<br /> | ||
[[5erv]] - rGeph E domain + ADP + W + WO4<br /> | [[5erv]] - rGeph E domain + ADP + W + WO4<br /> | ||
+ | [[6fgc]] - rGeph E domain + artesunate + ADP<br /> | ||
+ | [[6fgd]] - rGeph E domain + artemether + ADP<br /> | ||
[[1thc]] - rGeph N terminal<br /> | [[1thc]] - rGeph N terminal<br /> | ||
Revision as of 09:24, 9 July 2019
|
3D structures of gephyrin
Updated on 09-July-2019
2fu3, 5erq, 4pd0 - rGeph E domain 318-736 - rat
2fts, 4pd1, 1t3e, 4u91 - rGeph E domain + glycine receptor peptide
6hso - rGeph E domain + glycine receptor peptide + ADP<br /
4tk1, 4tk2, 4tk3, 4tk4, 4u90 - rGeph E domain + GABA receptor peptide
6hsn - rGeph E domain + GABA receptor peptide + ADP
5ers - rGeph E domain + AMP
5ert, 5err - rGeph E domain + ADP
5eru - rGeph E domain + ADP + Mo + MoO4
5erv - rGeph E domain + ADP + W + WO4
6fgc - rGeph E domain + artesunate + ADP
6fgd - rGeph E domain + artemether + ADP
1thc - rGeph N terminal
References
- ↑ Tyagarajan SK, Fritschy JM. Gephyrin: a master regulator of neuronal function? Nat Rev Neurosci. 2014 Mar;15(3):141-56. doi: 10.1038/nrn3670. PMID:24552784 doi:http://dx.doi.org/10.1038/nrn3670
- ↑ Hales CM, Rees H, Seyfried NT, Dammer EB, Duong DM, Gearing M, Montine TJ, Troncoso JC, Thambisetty M, Levey AI, Lah JJ, Wingo TS. Abnormal gephyrin immunoreactivity associated with Alzheimer disease pathologic changes. J Neuropathol Exp Neurol. 2013 Nov;72(11):1009-15. doi:, 10.1097/01.jnen.0000435847.59828.db. PMID:24128675 doi:http://dx.doi.org/10.1097/01.jnen.0000435847.59828.db
- ↑ Maric HM, Kasaragod VB, Haugaard-Kedstrom L, Hausrat TJ, Kneussel M, Schindelin H, Stromgaard K. Design and Synthesis of High-Affinity Dimeric Inhibitors Targeting the Interactions between Gephyrin and Inhibitory Neurotransmitter Receptors. Angew Chem Int Ed Engl. 2014 Nov 20. doi: 10.1002/anie.201409043. PMID:25413248 doi:http://dx.doi.org/10.1002/anie.201409043